Detailed Information
Cited 6 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04
- Authors
- Modi, S[Modi, Shanu]; Niikura, N[Niikura, Naoki]; Yamashita, T[Yamashita, Toshinari]; Jacot, W[Jacot, William]; Sohn, J[Sohn, Joohyuk]; Tokunaga, E[Tokunaga, Eriko]; Vidal, MJ[Vidal, Maria Jesus]; Park, YH[Park, Yeon Hee]; Lee, KS[Lee, Keun Seok]; Chae, Y[Chae, Yeesoo]; Ueno, NT[Ueno, Naoto T.]; Prat, A[Prat, Aleix]; Suto, F[Suto, Fumitaka]; Kuwahara, Y[Kuwahara, Yusuke]; McEwen, R[McEwen, Robert]; Feng, WQ[Feng, Wenqin]; Goto, H[Goto, Hiroki]; Orbegoso, C[Orbegoso, Cecilia]; Cameron, DA[Cameron, David A.]; Tsurutani, J[Tsurutani, Junji]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.